There are three upcoming developments that could all "put a...

There are three upcoming developments that could all "put a rocket under the share price" over the next six months. Approval of Recell Go is only one of them. IMO, whether Recell Go is appoved on May 30, 2024 or is delayed for another year or so is the least significant of the three. The two more significant ones in the short term (6 months) are:

1. VAC success. I found a very good discussion of the VAC process (see following link: https://rccf.com/navigating-the-value-analysis-committee/). It indicates that the process is typically 3 to 6 months in duration. We should start seeing significant success this quarter as many of the 100 trauma centers currently going through the VAC process reach conclusion and more centers are under way. It is this success that should result in an increase in the growth rate from the current 50% to more like 70-80%, in order to achieve the recently guided 57-69% for FY24.
2. Clear guidance in the February 2024 earnings call on the quarter in 2025 in which Avita achieves positive cash flow and becomes profitable.

It may take a little more than six months before we start to see significant positive developments on international expansion, and the financial benefits of Recell Go, if approved in May.

All in all, a lot to look forward to.